CD38-directed Cytolytic Antibody [EPC]

17357 reported adverse events

Drugs of this class: DARATUMUMAB DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT) ISATUXIMAB

These side effects are most commonly reported by patients taking drugs of the CD38-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 INFUSION RELATED REACTION 1600
1 PLASMA CELL MYELOMA 1149
2 PNEUMONIA 1004
3 OFF LABEL USE 1003
4 NEUTROPENIA 751
5 DEATH 737
6 DIARRHOEA 724
7 FATIGUE 690
8 DYSPNOEA 674
9 PYREXIA 651
See all common reactions for CD38-directed Cytolytic Antibody [EPC]

Drugs of the CD38-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CROSSMATCH INCOMPATIBLE 45 0.8036
1 SARS-COV-2 SEPSIS 8 0.5714
2 COOMBS INDIRECT TEST POSITIVE 30 0.5085
3 CEREBELLAR HAEMANGIOMA 7 0.3889
4 PLASMA CELL MYELOMA REFRACTORY 11 0.3235
5 AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANT 5 0.2273
6 PLASMA CELLS DECREASED 6 0.2000
7 RESPIROVIRUS TEST POSITIVE 10 0.2000
8 LIGHT CHAIN ANALYSIS DECREASED 7 0.1892
9 PSEUDOMYOPIA 8 0.1739
See all enriched reactions for CD38-directed Cytolytic Antibody [EPC]